Tirzepatide Reduces Diabetic Eye Complications 36-69% vs GLP-1 Drugs Including NAION
Tirzepatide was associated with 40% lower DR (HR 0.60), 37% lower DME (HR 0.63), 64% lower VH/RD (HR 0.36), 69% lower NAION (HR 0.31), and 56% lower vision-saving intervention need vs non-GIP GLP-1 RAs.
Quick Facts
What This Study Found
Tirzepatide vs non-GIP GLP-1 RA (102,590 per cohort): DR HR 0.60 (0.54-0.65); DME HR 0.63 (0.52-0.74); VH/RD HR 0.36 (0.23-0.55); vision-saving interventions HR 0.44 (0.32-0.60); NAION HR 0.31 (0.15-0.64).
Key Numbers
How They Did This
Nationwide retrospective cohort (June 2022-June 2025), 102,590 matched pairs, tirzepatide vs non-GIP GLP-1 RA, propensity-score matched for demographics/comorbidities/medications/ophthalmic encounters, 36-month follow-up.
Why This Research Matters
This is the first large study showing tirzepatide's broad ocular protective effects — and notably shows it REDUCES NAION risk rather than increasing it.
The Bigger Picture
If confirmed, tirzepatide could be the first drug shown to comprehensively protect against diabetic eye disease AND the rare optic nerve condition NAION — reversing earlier safety concerns about GLP-1 drugs.
What This Study Doesn't Tell Us
Retrospective observational. Short tirzepatide market exposure. Cannot determine if GIP agonism drives the protection. Active comparator design means relative, not absolute, risk.
Questions This Raises
- ?Does GIP receptor activation directly protect retinal and optic nerve cells?
- ?How does tirzepatide's NAION-protective effect reconcile with semaglutide NAION risk?
- ?Should ophthalmologists specifically recommend tirzepatide for diabetic eye disease?
Trust & Context
- Key Stat:
- 69% less NAION While semaglutide raised NAION concerns, tirzepatide showed 69% LOWER NAION risk vs GLP-1-only drugs — a remarkable reversal
- Evidence Grade:
- Very large propensity-matched cohort with multiple consistent subanalyses. Important evidence but observational.
- Study Age:
- Published in 2025.
- Original Title:
- Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Published In:
- Ophthalmology. Retina (2026)
- Authors:
- Hong, Alexander T(2), Lin, Forest(2), Keenan, Jeremy D, Stewart, Jay M
- Database ID:
- RPEP-15304
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide protect diabetic patients' eyes?
Dramatically. This study of 205,000 patients found tirzepatide reduced diabetic eye disease by 36-69% compared to other GLP-1 drugs, including a 69% reduction in a rare optic nerve condition (NAION).
What about the NAION concern with semaglutide?
Interestingly, while semaglutide has been linked to INCREASED NAION risk, tirzepatide showed the opposite — 69% LOWER risk. The GIP receptor activity unique to tirzepatide may explain this protective effect.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15304APA
Hong, Alexander T; Lin, Forest; Keenan, Jeremy D; Stewart, Jay M. (2026). Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.. Ophthalmology. Retina. https://doi.org/10.1016/j.oret.2026.02.002
MLA
Hong, Alexander T, et al. "Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.." Ophthalmology. Retina, 2026. https://doi.org/10.1016/j.oret.2026.02.002
RethinkPeptides
RethinkPeptides Research Database. "Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptid..." RPEP-15304. Retrieved from https://rethinkpeptides.com/research/hong-2026-ocular-outcomes-with-tirzepatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.